Introduction

A Feasibility Study for Pharmaceuticals & Biologics helps investors assess demand, production economics, regulation, supply chains, and investment risk. Africa offers a major opportunity for local medicine manufacturing. Yet the market remains highly dependent on imports. More than 70% of medicines consumed in Africa are imported.

Aviaan supports investors with structured Market Research Services and feasibility analysis for pharmaceutical projects. The approach combines market intelligence, financial modelling, regulatory review, operational assessment, and investment analysis. This helps decision-makers test commercial viability before committing capital.

The opportunity spans South Africa, Nigeria, Kenya, Egypt, Morocco, Ghana, Ethiopia, Tanzania, Uganda, Zambia, Côte d’Ivoire, and Botswana. Each market has different demand patterns, regulatory systems, manufacturing capabilities, and distribution structures.

Market Overview & Industry Insights

Africa's pharmaceutical sector has strong structural demand. However, local manufacturing remains concentrated in a limited number of markets. Investment decisions therefore require careful analysis of capacity, product selection, regulation, pricing, and regional access.

• Annual market opportunity: Africa's medicines and vaccines market is estimated at approximately US$50 billion annually, according to Africa CDC.
• Import dependence: More than 70% of pharmaceuticals consumed in Africa are imported, creating a clear local manufacturing opportunity.
• Manufacturing footprint: UNCTAD reported about 690 pharmaceutical manufacturing facilities, with eight countries accounting for 85% of them.
• Current manufacturer registry: Africa CDC's live registry lists 581 manufacturers across 34 countries. Pharmaceuticals account for 460 records, or 79% of the registry.
• Biologics capacity: The Africa CDC registry currently identifies 23 biologics and vaccine manufacturers, showing a smaller base than conventional pharmaceutical manufacturing.
• API dependence: Africa imports more than 95% of its active pharmaceutical ingredients, highlighting supply-chain and production risks.
• Facility utilisation: Many African pharmaceutical facilities operate at only 30%–60% capacity, compared with more than 70% in advanced economies.
• Local cost opportunity: Research cited by UNCTAD found that tablets, capsules, and creams produced in Ethiopia and Nigeria could be 15% cheaper than comparable imports from India.
• Investment position: Africa captures only around 5% of global greenfield FDI in pharmaceutical manufacturing.
• Policy ambition: African leaders have committed to meeting at least 60% of the continent's health-product needs through local manufacturing by 2040.
• Manufacturing expansion: Africa CDC reported in 2025 that eight vaccine antigens were expected to enter the market between 2025 and 2030.
• Industry intelligence: Africa CDC's AMMINA platform initially covered more than 700 manufacturers and 2,500 health products across 18 AU Member States.

These figures show both opportunity and risk. Investors should not treat Africa as one uniform pharmaceutical market. Product selection, country choice, scale, procurement access, and regulatory readiness can materially change project economics.

Go-To-Market Strategy

Aviaan builds market-entry strategies around product economics and commercial access. The analysis connects demand with customer segments, pricing, channels, competitors, and regulatory requirements.

• Market Entry Assessment – Identify priority countries, product categories, customer segments, and entry barriers.
• Competitive Benchmarking – Compare local and international manufacturers on pricing, products, quality, capacity, and distribution.
• Pricing & Positioning – Test price points against public procurement, private healthcare, wholesalers, and institutional buyers.
• Distribution Planning – Evaluate distributors, hospitals, pharmacies, tenders, regional hubs, and cross-border channels.
• Commercialisation Roadmap – Prioritise products, launch markets, partnerships, regulatory milestones, and scale-up actions.

For example, a project covering South Africa and Nigeria may require a different commercial model from one focused on Kenya and Tanzania. Regional expansion also needs careful assessment of local registration requirements.

Feasibility Study for Pharmaceuticals & Biologics

Aviaan evaluates pharmaceutical and biologics projects through an integrated commercial, technical, operational, and financial model.

• Demand assessment: Quantify demand by therapeutic category, product type, customer group, and geography.
• Technical feasibility: Review technology, production processes, GMP requirements, equipment, cleanrooms, utilities, and quality systems.
• Operational feasibility: Assess site suitability, workforce, suppliers, logistics, warehousing, and production capacity.
• Regulatory assessment: Map product registration, manufacturing licences, GMP expectations, pharmacovigilance, and quality requirements.
• Financial viability: Build capital expenditure, operating cost, revenue, cash flow, margins, break-even, and return scenarios.
• Investment analysis: Test funding requirements against project scale, capacity utilisation, pricing, and expected commercial returns.
• Risk assessment: Model supply-chain, regulatory, currency, procurement, technology, pricing, and execution risks.

Biologics need deeper technical analysis than many conventional formulations. Cold-chain requirements, specialised equipment, quality controls, technology transfer, and skilled personnel can significantly affect project economics.

Market Research for Pharmaceuticals & Biologics

Aviaan uses market research to convert fragmented pharmaceutical data into investment decisions.

• Customer analysis: Segment hospitals, pharmacies, distributors, government buyers, insurers, and healthcare institutions.
• Competitor intelligence: Benchmark product portfolios, manufacturing capacity, prices, quality positioning, and geographic reach.
• Market sizing: Estimate addressable demand using product, therapy, customer, and country-level data.
• Demand forecasting: Build scenarios based on disease burden, procurement patterns, healthcare access, and treatment adoption.
• Pricing analysis: Compare local prices, imported products, tender prices, and distributor margins.
• Supply-chain research: Map API suppliers, packaging inputs, logistics providers, cold-chain networks, and distribution partners.
• Opportunity identification: Prioritise products and markets where demand, regulatory feasibility, and commercial economics align.

Africa CDC's manufacturer registry can also strengthen competitor mapping. Its current database provides country-level visibility across pharmaceutical, biologics, API, diagnostics, and medical-device categories.

Business Plan for Pharmaceuticals & Biologics

Aviaan prepares investor-ready business plans around measurable commercial assumptions.

• Financial modelling: Develop integrated income statements, cash flows, balance sheets, working capital, and sensitivity scenarios.
• Revenue projections: Model sales by product, country, channel, price, volume, and ramp-up period.
• Operational planning: Define manufacturing capacity, staffing, procurement, quality systems, logistics, and facility requirements.
• Funding strategy: Determine equity, debt, strategic investment, grants, development finance, and other potential funding routes.
• Growth planning: Build phased expansion plans for additional products, capacity, countries, partnerships, and export markets.

The model also tests downside scenarios. These may include delayed registration, lower capacity utilisation, higher API costs, currency volatility, or slower sales adoption.

How Aviaan Uses Primary Research

Secondary research provides scale. Primary research provides market reality.

Aviaan can use structured interviews, surveys, expert consultations, supplier discussions, competitor checks, retail audits, and field research. These methods help validate assumptions that public datasets may not capture.

For pharmaceutical projects, primary research can test actual distributor margins, procurement preferences, product availability, purchasing cycles, price sensitivity, and regulatory bottlenecks. Supplier discussions can also validate lead times and minimum order quantities.

This approach is especially useful when assessing markets such as Egypt, Morocco, Ghana, Ethiopia, Uganda, Zambia, Côte d’Ivoire, and Botswana. Local market conditions can differ sharply from regional averages.

Our Experience & Credentials

Aviaan's consulting approach combines commercial research, financial analysis, feasibility assessment, and strategic planning. For pharmaceutical and biologics projects, the focus remains on measurable assumptions and investment decisions. Assignments are structured to protect commercial confidentiality while demonstrating relevant sector expertise.

• Pharmaceutical Market Research – South Africa – Assessed demand, competitors, pricing, distribution channels, and market-entry opportunities for a pharmaceutical product portfolio.
• Manufacturing Feasibility Study – Nigeria – Evaluated plant economics, capacity requirements, regulatory considerations, operating costs, and investment viability.
• Pharmaceutical Business Plan – Kenya – Developed financial projections, commercial strategy, funding requirements, and phased market expansion plans.
• Biologics Investment Advisory – Egypt – Analysed market opportunity, production economics, technology requirements, investment scenarios, and commercial risks.
• Pharmaceutical Commercial Due Diligence – Morocco – Reviewed market attractiveness, competitive positioning, customer access, operational capability, and financial assumptions.

Conclusion

A Feasibility Study for Pharmaceuticals & Biologics is critical before investing in African pharmaceutical manufacturing. The opportunity is substantial, but market fragmentation, import dependence, regulatory complexity, capacity constraints, and supply-chain risks require careful analysis.

The strongest projects will connect product selection with local demand, efficient manufacturing, quality systems, reliable procurement, and regional expansion. Countries such as South Africa, Nigeria, Kenya, Egypt, Morocco, Ghana, Ethiopia, Tanzania, Uganda, Zambia, Côte d’Ivoire, and Botswana can offer different routes to market.

Africa's policy direction is also becoming more supportive of local production. The 2026 African Union declaration reaffirmed the goal of reaching at least 60% local health-product manufacturing by 2040.

Aviaan can help investors test the opportunity before capital is committed. Contact Aviaan to develop a practical feasibility study, market research programme, or investment-ready business plan for your pharmaceutical or biologics project.

FAQs

1. Why is a feasibility study important for pharmaceutical projects in Africa?

It tests market demand, manufacturing requirements, regulatory conditions, investment costs, operating economics, and financial returns before major capital is committed.

2. Which African countries are attractive for pharmaceutical manufacturing?

The right country depends on the product and business model. South Africa, Nigeria, Egypt, Morocco, Kenya, Ethiopia, and other markets have different manufacturing ecosystems and market-access conditions.

3. How much does a pharmaceutical feasibility study cost?

The cost depends on project size, countries covered, product categories, research depth, technical requirements, and financial modelling complexity. A tailored scope provides a more accurate fee.

4. How long does a pharmaceutical feasibility study take?

A focused study may take several weeks. Larger projects involving multiple countries, primary research, technical assessment, and detailed financial modelling require more time.

5. Should investors conduct market research before building a pharmaceutical plant?

Yes. Market research should precede major plant investment. It helps validate product demand, pricing, competition, procurement channels, and potential capacity requirements.

Related Service Pages

• Feasibility Study Services
• Business Plan Services
• Market Research Services

Related Blogs

Market Research and Feasibility Study for Solar Renewable Energy Equipment in Africa
Market Research and Feasibility Study for Battery Recycling Energy Storage Systems in Africa
Market Research and Feasibility Study for Industrial Chemicals Resins in Africa
Market Research and Feasibility Study for Adhesives Sealants Coatings in Africa
Market Research and Feasibility Study for Food Processing Packaged Foods in Africa
Market Research and Feasibility Study for Medical Disposables Healthcare Products in Africa
Market Research and Feasibility Study for Packaging Manufacturing in Africa
Market Research and Feasibility Study for Plastic Polymer Products in Africa
Market Research and Feasibility Study for Cold Storage Logistics Related Manufacturing in Africa
Market Research and Feasibility Study for Semiconductors Manufacturing in Africa
Market Research and Feasibility Study for Electric Vehicle EV Components Manufacturing in Africa
Market Research and Feasibility Study for Industrial Automation Robotics in Africa
Market Research and Feasibility Study for Medical Devices in Africa
Market Research and Feasibility Study for Aerospace Defense Equipment in Africa
Market Research and Feasibility Study for Specialty Chemicals in Africa